Even the heterozygous deletion of CDKN2A/B is associated with poor outcomes, and meningiomas with increased mRNA expression of CDKN2A/B are also linked to worse prognosis with significant resistance to CDK inhibitors [93]. The gene discussed is CDKN2A; the disease is meningioma.